Novo Nordisk Pins Turnaround Hopes on London Strategy Day as Buybacks and Paediatric Data Offer Ballast

Novo Nordisk, now trading as Novo, holds a capital markets day on 21 September as shares sit 34% below their January high and analysts stay cautious.

Novo Nordisk has spent the past fortnight trying to steady a stock that has lost significant ground, and investors are now counting down to 21 September, when management will lay out its revamped corporate strategy in London. The capital markets day arrives barely a week after the Danish drugmaker confirmed it will trade under the shortened name "Novo", complete with the tagline "Lasting Health Starts Now" and a refreshed corporate culture dubbed "The Novo Way". Management says the overhaul is designed to sharpen focus, speed and impact across the group.

The timing is hardly accidental. The shares have come under heavy pressure, last changing hands at EUR 36.46 — roughly 34% below their 52-week high of EUR 54.86 set in January. The stock also sits about 11% beneath its 50-day moving average of EUR 40.83, a clear signal of how firmly the near-term downtrend has taken hold. In European trading yesterday the paper closed 0.7% lower at EUR 36.45.

Analysts Split on Whether the Bad News Is Priced In

Deutsche Bank Research reiterated its sell rating on Tuesday, keeping a price target of DKK 265 — a call first issued in late August. Analyst Emmanuel Papadakis pointed to soft weekly prescription data in the United States as the chief reason for caution. His colleague Thibault Boutherin has argued that the current valuation fails to fully reflect the company's muted medium-term growth prospects.

Morgan Stanley has struck a similar chord. The bank downgraded the stock last Friday, citing a lack of positive catalysts ahead of the capital markets day, and the shares have shed 1.7% since. The central worry is Novo's heavy reliance on its blockbuster semaglutide. Morgan Stanley calculates the compound will account for roughly 75% of group revenue in 2026, and even as patent expiries begin to bite in the following decade, the analysts still model a 59% revenue contribution. The looming loss of patent protection from the early-to-mid 2030s weighs on the company's long-term value in their view.

Paediatric Trial Delivers a Win for Semaglutide

Against that backdrop, the company continues to push its core molecule forward in the clinic. On 7 September Novo released data from the Phase 3 STEP Young study, which showed that 40.4% of treated children were no longer living with obesity after 68 weeks of once-weekly semaglutide. Not a single participant in the placebo arm achieved the same outcome. Safety and tolerability matched observations from earlier trials in adults and adolescents, reinforcing the drug's efficacy profile in younger patients.

Milan Congress to Put Pipeline Under the Microscope

Scientific momentum extends beyond the paediatric readout. Between 28 September and 2 October, Novo will present 44 abstracts at the EASD European diabetes congress in Milan. Real-world clinical data and progress across the cardiometabolic pipeline take centre stage, including results for the oral Wegovy pill and next-generation amylin treatments. Fresh findings on semaglutide, the combination therapy CagriSema and zenagamtide are also on the agenda. The sheer volume of data could become a litmus test of whether the pipeline can still meet the market's lofty expectations.

Buyback Programme Presses On Regardless

Even with sentiment frayed, Novo has shown no sign of slowing its share repurchase programme. As of 11 September, the group had bought back just over 33 million B-shares since the start of February at an average price of DKK 281.89, translating into a transaction volume of roughly DKK 9.33 billion within the DKK 15 billion twelve-month framework. The steady pace of buying suggests management remains convinced of the company's long-term valuation despite the share price weakness.

Whether the rebranding, the Milan data and the buyback engine can together engineer a change of direction may hinge on how convincingly management frames its strategy on 21 September. The stock has fallen 17% since the start of the year, and the coming fortnight will reveal whether Novo can win back the confidence of a market that has grown increasingly sceptical.